Dr. Weber on Nivolumab in the Adjuvant Setting for Melanoma

Jeffrey S. Weber, MD, PhD
Published: Friday, Oct 20, 2017



Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the use of nivolumab (Opdivo) in the adjuvant setting for the treatment of patients with melanoma.

According to Weber, nivolumab as an adjuvant therapy for patients with high-risk melanoma was well tolerated. A third of the patients relapsed after 5 years, which was considered an improvement, explains Weber.

<<< View more from the World Congress of Melanoma


Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the use of nivolumab (Opdivo) in the adjuvant setting for the treatment of patients with melanoma.

According to Weber, nivolumab as an adjuvant therapy for patients with high-risk melanoma was well tolerated. A third of the patients relapsed after 5 years, which was considered an improvement, explains Weber.

<<< View more from the World Congress of Melanoma

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x